Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
9 results
Search Results
Item Patient-Reported Outcomes (Pros) Of Cemiplimab Vs Chemotherapy In Advanced Non-Small Cell Lung Cancer (Ansclc): EMPOWER-Lung 1 Histology Subgroups(2022) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R.Item Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial(2022) Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Nechaeva, M.; Schenker, M.; Cicin, I.; Ho, G. F.; Kulyaba, Y.; Dvorkin, M.; Zyuhal, K.; Scheusan, R. I.; Li, S.; Pouliot, J-F.; Seebach, F.; Lowy, I.; Gullo, G.; Rietschel, P.Item The Health Impact Projection Model Of The Pd-1/Pd-L1 Inhibitor Class In Cancer Care In Turkey(2022) Akpamuk, U.; Hughes, R.; Swales, O.; Oyan, B.; Kilickap, S.; Demirci, U.; Sendur, M.A.; Sonmez, O.; Yazici, O.; Malhan, S.; Oksuz, E.; Tuzer, E.; Ersoy, Akyol B.; Poellinger, B.Item Patient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 Subpopulation(2022) Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G.Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer(2020) Demirci, U.; Erturk, I.; Arslan, C.; Bilici, A.; Cevik, D.; Cicin, I.; Dane, F.; Dolek, B.; Kaplan, M.; Karadurmus, N.; Kose, F.; Sendur, M.; Urun, Y.; Kilickap, S.Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvilli, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%(2019) Sezer, A.; Gogishvili, M.; Bentsion, D.; Kilickap, S.; Lowczak, A.; Gumus, M.; Gladkow, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Lee, S.; Li, S.; Snodgrass, P.; Navarro, M.; Lowy, I.; Rietschel, P.